From NAFLD to MAFLD: Definition, Pathophysiological Basis and Cardiovascular Implications
出版年份 2023 全文链接
标题
From NAFLD to MAFLD: Definition, Pathophysiological Basis and Cardiovascular Implications
作者
关键词
-
出版物
Biomedicines
Volume 11, Issue 3, Pages 883
出版商
MDPI AG
发表日期
2023-03-14
DOI
10.3390/biomedicines11030883
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Metabolic dysfunction-associated fatty liver disease is associated with an increase in systolic blood pressure over time: linear mixed-effects model analyses
- (2023) Kazuma Mori et al. HYPERTENSION RESEARCH
- Metabolic biomarkers related to cardiac dysfunction in metabolic-dysfunction-associated fatty liver disease: a cross-sectional analysis
- (2022) Abdulrahman Ismaiel et al. Nutrition & Diabetes
- MAFLD Predicts the Risk of Cardiovascular Disease Better than NAFLD in Asymptomatic Subjects with Health Check-Ups
- (2022) Hyoeun Kim et al. DIGESTIVE DISEASES AND SCIENCES
- A significant risk of metabolic dysfunction-associated fatty liver disease plus diabetes on subclinical atherosclerosis
- (2022) Rieko Bessho et al. PLoS One
- Impaired coagulation, liver dysfunction and COVID-19: Discovering an intriguing relationship
- (2022) Damiano D’Ardes et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Is it necessary to target lipid metabolism in different organs for effective treatment of NASH?—the results of the Pan-PPAR Lanifibranor trial
- (2022) Amalia Gastaldelli Hepatobiliary Surgery and Nutrition
- Heterogeneity of non-alcoholic fatty liver disease (NAFLD): Implication for cardiovascular risk stratification
- (2022) Francesco Baratta et al. ATHEROSCLEROSIS
- Long-term cardiovascular outcomes differ across metabolic dysfunction-associated fatty liver disease subtypes among middle-aged population
- (2022) Hokyou Lee et al. Hepatology International
- Cardiometabolic characterization in metabolic dysfunction–associated fatty liver disease
- (2022) Carolina M. Perdomo et al. Frontiers in Medicine
- Type 2 diabetes mellitus in metabolic-associated fatty liver disease vs. type 2 diabetes mellitus non-alcoholic fatty liver disease: a longitudinal cohort analysis
- (2022) Mark Muthiah et al. Annals of Hepatology
- Blood pressure stratification for predicting liver fibrosis risk in metabolic dysfunction associated fatty liver disease
- (2022) Jing Liu et al. Annals of Hepatology
- The Interplay between Angiopoietin-Like Proteins and Adipose Tissue: Another Piece of the Relationship between Adiposopathy and Cardiometabolic Diseases?
- (2021) Simone Bini et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- NAFLD and Cardiovascular Diseases: Epidemiological, Mechanistic and Therapeutic Considerations
- (2021) David Niederseer et al. Journal of Clinical Medicine
- Role of liver sinusoidal endothelial cells in liver diseases
- (2021) Jordi Gracia-Sancho et al. Nature Reviews Gastroenterology & Hepatology
- Non‐alcoholic fatty liver disease‐related risk of cardiovascular disease and other cardiac complications
- (2021) Christopher D. Byrne et al. DIABETES OBESITY & METABOLISM
- Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial
- (2021) Stephen A. Harrison et al. NATURE MEDICINE
- Hepatic sexual dimorphism — implications for non-alcoholic fatty liver disease
- (2021) Philippe Lefebvre et al. Nature Reviews Endocrinology
- Efficacy of elafibranor in patients with liver abnormalities especially non-alcoholic steatohepatitis: a systematic review and meta-analysis
- (2021) Adnan Malik et al. Clinical Journal of Gastroenterology
- Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002–2033: the ITA.LI.CA database
- (2021) Alessandro Vitale et al. GUT
- Metabolic-associated fatty liver disease and major adverse cardiac events in patients with chronic coronary syndrome: a matched case–control study
- (2021) Hui-Hui Liu et al. Hepatology International
- MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease
- (2020) Mohammed Eslam et al. GASTROENTEROLOGY
- Cilofexor, a Nonsteroidal FXR Agonist, in Non‐Cirrhotic Patients with Nonalcoholic Steatohepatitis: A Phase 2 Randomized Controlled Trial
- (2020) Keyur Patel et al. HEPATOLOGY
- Liraglutide improves memory in obese patients with prediabetes or early type 2 diabetes: a randomized, controlled study
- (2020) Francesco Vadini et al. INTERNATIONAL JOURNAL OF OBESITY
- A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement
- (2020) Mohammed Eslam et al. JOURNAL OF HEPATOLOGY
- Association between nonalcoholic fatty liver disease and extrahepatic cancers: a systematic review and meta-analysis
- (2020) Shou-Sheng Liu et al. Lipids in Health and Disease
- Effect of a ketogenic diet on hepatic steatosis and hepatic mitochondrial metabolism in nonalcoholic fatty liver disease
- (2020) Panu K. Luukkonen et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Nonalcoholic Steatohepatitis Is the Most Rapidly Increasing Indication for Liver Transplantation in the United States
- (2020) Zobair M. Younossi et al. Clinical Gastroenterology and Hepatology
- Association of Hepatic Steatosis with Major Adverse Cardiovascular Events, Independent of Coronary Artery Disease
- (2020) Nandini M. Meyersohn et al. Clinical Gastroenterology and Hepatology
- The association of non‐alcoholic fatty liver disease and cardiac structure and function—Framingham Heart Study
- (2020) Laura S. Chiu et al. LIVER INTERNATIONAL
- Depression and Cognitive Impairment—Extrahepatic Manifestations of NAFLD and NASH
- (2020) Martina Colognesi et al. Biomedicines
- Improving Outcomes of Bariatric Surgery in Patients With Cirrhosis in the United States
- (2020) Vijay S. Are et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease
- (2020) Mohammed Eslam et al. Hepatology International
- Unhealthy lifestyle habits and physical inactivity among Asian patients with non‐alcoholic fatty liver disease
- (2020) Xinrong Zhang et al. LIVER INTERNATIONAL
- AGA Clinical Practice Update on Lifestyle Modification Using Diet and Exercise to Achieve Weight Loss in the Management of Nonalcoholic Fatty Liver Disease: Expert Review
- (2020) Zobair M. Younossi et al. GASTROENTEROLOGY
- The changing scenario of hepatocellular carcinoma in Italy: an update
- (2020) Francesca Garuti et al. LIVER INTERNATIONAL
- Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention
- (2020) Daniel Q. Huang et al. Nature Reviews Gastroenterology & Hepatology
- The Association between Nonalcoholic Fatty Liver Disease and Stroke: Results from the Korean Genome and Epidemiology Study (KoGES)
- (2020) Yun-Jung Yang et al. International Journal of Environmental Research and Public Health
- A Phase 2 Double Blinded, Randomized Controlled Trial of Saroglitazar in Patients With Nonalcoholic Steatohepatitis
- (2020) Mohammad Shadab Siddiqui et al. Clinical Gastroenterology and Hepatology
- Nonalcoholic Fatty Liver Disease and the Heart
- (2019) Eric P. Stahl et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes Mellitus
- (2019) Lee-Lee Lai et al. DIGESTIVE DISEASES AND SCIENCES
- Does nonalcoholic fatty liver disease cause cardiovascular disease? Current knowledge and gaps
- (2019) Raul D. Santos et al. ATHEROSCLEROSIS
- Accumulation of free cholesterol and oxidized low-density lipoprotein is associated with portal inflammation and fibrosis in nonalcoholic fatty liver disease
- (2019) Cheng-Maw Ho et al. Journal of Inflammation-London
- Extrahepatic Manifestations of Nonalcoholic Fatty Liver Disease
- (2019) Andrew A. Li et al. Gut and Liver
- New Insights in the Control of Low-Density Lipoprotein Cholesterol to Prevent Cardiovascular Disease
- (2019) Julius L. Katzmann et al. Current Cardiology Reports
- Cardiovascular Risk in Non-Alcoholic Fatty Liver Disease: Mechanisms and Therapeutic Implications
- (2019) Claudio Tana et al. International Journal of Environmental Research and Public Health
- Non-alcoholic fatty liver disease and cardiovascular disease: assessing the evidence for causality
- (2019) Martijn C. G. J. Brouwers et al. DIABETOLOGIA
- Refining the role of epicardial adipose tissue in non-alcoholic fatty liver disease
- (2019) Mohammed Eslam et al. Hepatology International
- Bile acids in glucose metabolism and insulin signalling — mechanisms and research needs
- (2019) Tiara R. Ahmad et al. Nature Reviews Endocrinology
- Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease
- (2019) Gordon I. Smith et al. JOURNAL OF CLINICAL INVESTIGATION
- Serum Angiopoietin-like peptide 4 levels in patients with hepatic steatosis
- (2018) Özgür Altun et al. CYTOKINE
- Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030
- (2018) Chris Estes et al. JOURNAL OF HEPATOLOGY
- Human-based systems: Mechanistic NASH modelling just around the corner?
- (2018) Joost Boeckmans et al. PHARMACOLOGICAL RESEARCH
- Association of circulating ANGPTL 3, 4, and 8 levels with medical status in a population undergoing routine medical checkups: A cross-sectional study
- (2018) Jun Morinaga et al. PLoS One
- An Overview and Update on Obesity and the Obesity Paradox in Cardiovascular Diseases
- (2018) Andrew Elagizi et al. PROGRESS IN CARDIOVASCULAR DISEASES
- SIGNIFICANCE OF URINARY 11-DEHYDRO-THROMBOXANE B2 IN AGE-RELATED DISEASES: FOCUS ON ATHEROTHROMBOSIS
- (2018) Paola Simeone et al. AGEING RESEARCH REVIEWS
- Systematic review with meta-analysis: risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases
- (2018) Jonathan G. Stine et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial
- (2018) Patrick M O'Neil et al. LANCET
- Nonalcoholic steatohepatitis, obesity, and cardiac dysfunction
- (2018) Sherin E. Mathews et al. Current Opinion in Endocrinology Diabetes and Obesity
- Complete Resolution of Nonalcoholic Fatty Liver Disease After Bariatric Surgery: A Systematic Review and Meta-Analysis
- (2018) Yung Lee et al. Clinical Gastroenterology and Hepatology
- Liraglutide, sitagliptin and insulin glargine added to metformin: the effect on body weight and intrahepatic lipid in patients with type 2 diabetes mellitus and NAFLD
- (2018) Jinhua Yan et al. HEPATOLOGY
- Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial
- (2018) Arun Sanyal et al. LANCET
- The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
- (2017) Naga Chalasani et al. HEPATOLOGY
- Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: A systematic review
- (2017) Ryuki Hashida et al. JOURNAL OF HEPATOLOGY
- Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
- (2017) Rury R. Holman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Oxidative Stress Modulation Through Habitual Physical Activity
- (2016) Andrea Boccatonda et al. CURRENT PHARMACEUTICAL DESIGN
- Molecular Pathogenesis of NASH
- (2016) Alessandra Caligiuri et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Effect of liraglutide therapy on liver fat content in patients with inadequately controlled type 2 diabetes. The Lira-NAFLD study
- (2016) Jean-Michel Petit et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Hepatic Steatosis and Insulin Resistance, But Not Steatohepatitis, Promote Atherogenic Dyslipidemia in NAFLD
- (2016) Fernando Bril et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
- (2016) JOURNAL OF HEPATOLOGY
- Sinusoidal communication in liver fibrosis and regeneration
- (2016) Giusi Marrone et al. JOURNAL OF HEPATOLOGY
- Arterial stiffness and sedentary lifestyle: Role of oxidative stress
- (2016) Gianfranco Lessiani et al. VASCULAR PHARMACOLOGY
- Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis
- (2015) Eduardo Vilar-Gomez et al. GASTROENTEROLOGY
- Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009
- (2015) Zobair M. Younossi et al. HEPATOLOGY
- Nonalcoholic Fatty Liver Disease
- (2015) Mary E. Rinella JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
- (2015) Brent A Neuschwander-Tetri et al. LANCET
- Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23
- (2015) Chiara Degirolamo et al. NATURE REVIEWS DRUG DISCOVERY
- A Systematic Review of Bariatric Surgery in Patients with Liver Cirrhosis
- (2015) Ahmad Jan et al. OBESITY SURGERY
- The role of insulin resistance in nonalcoholic steatohepatitis and liver disease development – a potential therapeutic target?
- (2015) Paola Dongiovanni et al. Expert Review of Gastroenterology & Hepatology
- Postprandial lipemia as a cardiometabolic risk factor
- (2014) Angela Pirillo et al. CURRENT MEDICAL RESEARCH AND OPINION
- Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease
- (2014) Stefano Ballestri WORLD JOURNAL OF GASTROENTEROLOGY
- Pericardial Fat Is Associated With Prevalent Atrial Fibrillation
- (2010) George Thanassoulis et al. Circulation-Arrhythmia and Electrophysiology
- Prevalence of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among a Largely Middle-Aged Population Utilizing Ultrasound and Liver Biopsy: A Prospective Study
- (2010) Christopher D. Williams et al. GASTROENTEROLOGY
- Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway
- (2010) Nitika Arora Gupta et al. HEPATOLOGY
- Fatty liver, insulin resistance, and dyslipidemia
- (2008) Martin Adiels et al. Current Diabetes Reports
- Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice
- (2008) Catherine Postic et al. JOURNAL OF CLINICAL INVESTIGATION
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now